How could pharmacogenomics help improve patient survival?

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Rosell, 2006, Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway, Clin Cancer Res, 12, 7222, 10.1158/1078-0432.CCR-06-0627 Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055 Riely, 2006, Update on epidermal growth factor receptor mutations in non-small cell lung cancer, Clin Cancer Res, 12, 7232, 10.1158/1078-0432.CCR-06-0658 Rosell, 2006, Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going, Curr Opin Oncol, 18, 135, 10.1097/01.cco.0000208786.91947.eb Toschi, 2007, Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors, Oncologist, 12, 211, 10.1634/theoncologist.12-2-211 Cortes-Funes, 2005, Epidermal growth factor receptor activating mutations in Spanish gefitinibtreated non-small-cell lung cancer patients, Ann Oncol, 16, 1081, 10.1093/annonc/mdi221 Mitsudomi, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-smallcell lung cancer with postoperative recurrence, J Clin Oncol, 23, 2513, 10.1200/JCO.2005.00.992 Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 6829, 10.1200/JCO.2005.01.0793 Taron, 2005, Activating mutations in thetyrosinekinasedomainoftheepidermalgrowthfactor receptor are associated with improved survival in gefitinibtreated chemorefractory lung adenocarcinomas, Clin Cancer Res, 11, 5878, 10.1158/1078-0432.CCR-04-2618 Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073 Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res, 12, 5764, 10.1158/1078-0432.CCR-06-0714 Porter, 2006, Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways, Semin Cancer Biol, 16, 193, 10.1016/j.semcancer.2006.03.003 Ramirez, 2005, 14-3-3-sigma methylation in pretreatment serum circulating DNA of cisplatin-plusgemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group, J Clin Oncol, 23, 9105, 10.1200/JCO.2005.02.2905 Mizuno, 2002, Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers, Oncogene, 21, 2328, 10.1038/sj.onc.1205402 Mariatos, 2003, Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer, Cancer Res, 63, 7185 Isla, 2006, Mitotic checkpoint gene CHFR methylation in pretreatment serum DNA of docetaxel (doc)/cisplatin (cis)-treated stage IV non-small cell lung cancer (NSCLC) patients (p), J Clin Oncol, 24, 7056, 10.1200/jco.2006.24.18_suppl.7056 Rosell, 2002, DNA repair and cisplatin resistance in non-small-cell lung cancer, Lung Cancer, 38, 217, 10.1016/S0169-5002(02)00224-6 Rosell, 2004, Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB nonsmall cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery, Clin Cancer Res, 10, 4215s, 10.1158/1078-0432.CCR-040006 Rosell, 2003, Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer, Oncogene, 22, 3548, 10.1038/sj.onc.1206419 Lord, 2002, Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer, Clin Cancer Res, 8, 2286 Rosell, 2004, Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients, Clin Cancer Res, 10, 1318, 10.1158/1078-0432.CCR-03-0156 Ceppi, 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine, Ann Oncol, 17, 1818, 10.1093/annonc/mdl300 Cobo, 2007, Customizing cisplatinbased chemotherapy on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III randomized trial in non-small-cell lung cancer, J Clin Oncol, 10.1200/JCO.2006.09.7915 Quinn, 2003, BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis, Cancer Res, 63, 6221 Taron, 2004, BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer, Hum Mol Genet, 13, 2443, 10.1093/hmg/ddh260 de las Peñas, 2006, Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients, Ann Oncol, 17, 668, 10.1093/annonc/mdj135 Rosell-Costa, 2006, Clinical outcome of gemcitabine (gem)/cisplatin (cis)vs docetaxel (doc)/cistreated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age, J Clin Oncol, 24, 7055, 10.1200/jco.2006.24.18_suppl.7055